Three patients in the UK have received a 'groundbreaking' treatment for lupus, including Katie Tinkler, who received the treatment at University College London Hospital in London. (PA) A new ...
NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX), a ...
Margrit Wiesendanger, MD, PhD, discusses how lupus treatment is evolving from traditional therapies to more targeted options like biologics, with promising advances now being explored in clinical ...
Systemic lupus erythematosus, or lupus, is a complex autoimmune disease in which the immune system mistakenly attacks healthy ...
PETACH TIKVA, Israel, Dec. 12, 2024 /PRNewswire/ -- Isotopia is proud to announce a groundbreaking partnership with LIVEKIDNEY.BIO, a clinical-stage biotech innovator, to support the development of a ...
In light of litifilimab recently receiving FDA Breakthrough Therapy Designation for CLE, we spoke with experts to discuss diagnostic and treatment gaps in disease management.
Lupus treatment is different for different people. That’s because no two cases of lupus are the same — each person experiences lupus differently. That’s why it’s so important to work closely with your ...
Key Takeaways Lupus is a chronic autoimmune disease that can damage the skin, joints, kidneys and more Women ages 15 - 45 make up about 90% of lupus cases, with higher risks in some racial groups New ...
A multi-center clinical trial of investigational therapy, NKX019, for the treatment of lupus nephritis (LN, lupus-related kidney disease) is screening its first participant. The Ntrust-1 study is ...
Margrit Wiesendanger, MD, PhD, highlights how social determinants of health and equitable treatment access are critical to improving lupus outcomes, particularly in minority populations. The LUMINA ...
Two Teams Led by Drs. Deepak Rao and Alexandra-Chloe Villani and by Dr. Caroline Jefferies Will Explore Disease Heterogeneity, Looking Closer at Biomarkers and Treatment Response NEW YORK, Jan. 21, ...
Like in other chronic inflammatory disorders, achieving disease activity control in SLE requires the application of the treat-to-target strategy. This approach requires setting clear treatment targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results